BRIEF-Castle Biosciences Inc Says Tissuecypher® Provides Actionable Risk Insights That Influence Clinical Management And Prompt Risk-Aligned Intervention In Barrett’s Esophagus

Reuters

Oct 27, 2025

BRIEF-<a href="https://laohu8.com/S/CSTL">Castle Biosciences</a> Inc Says Tissuecypher® Provides Actionable Risk Insights That Influence Clinical Management And Prompt Risk-Aligned Intervention In Barrett’s Esophagus

Oct 26 (Reuters) - Castle Biosciences Inc CSTL.O:

NEW DATA AT AMERICAN COLLEGE OF GASTROENTEROLOGY ANNUAL MEETING SHOW TISSUECYPHER® PROVIDES ACTIONABLE RISK INSIGHTS THAT INFLUENCE CLINICAL MANAGEMENT AND PROMPT RISK-ALIGNED INTERVENTION IN BARRETT’S ESOPHAGUS
CASTLE BIOSCIENCES INC - TISSUECYPHER SHOWS 34% AND 62% FIVE-YEAR PROGRESSION RISK

Source text: ID:nGNX4gd6fY

Further company coverage: CSTL.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2578654818"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578654818\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578654818?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-27 03:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578654818","market":"nz","top_or_hot":-1,"title":"BRIEF-Castle Biosciences Inc Says Tissuecypher® Provides Actionable Risk Insights That Influence Clinical Management And Prompt Risk-Aligned Intervention In Barrett’s Esophagus","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/CSTL\">Castle Biosciences</a> Inc Says Tissuecypher® Provides Actionable Risk Insights That Influence Clinical Management And Prompt Risk-Aligned Intervention In Barrett’s Esophagus</title></head><body><p><span>Oct 26 (Reuters)</span><span> - </span>Castle Biosciences Inc <span>CSTL.O</span>:</p><ul><li><p>NEW DATA AT AMERICAN COLLEGE OF GASTROENTEROLOGY ANNUAL MEETING SHOW TISSUECYPHER® PROVIDES ACTIONABLE RISK INSIGHTS THAT INFLUENCE CLINICAL MANAGEMENT AND PROMPT RISK-ALIGNED INTERVENTION IN BARRETT’S ESOPHAGUS</p></li><li><p>CASTLE BIOSCIENCES INC - TISSUECYPHER SHOWS 34% AND 62% FIVE-YEAR PROGRESSION RISK</p></li></ul><p>Source text: <span>ID:nGNX4gd6fY</span></p><p>Further company coverage: <span>CSTL.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Castle Biosciences Inc Says Tissuecypher® Provides Actionable Risk Insights That Influence Clinical Management And Prompt Risk-Aligned Intervention In Barrett’s Esophagus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Castle Biosciences Inc Says Tissuecypher® Provides Actionable Risk Insights That Influence Clinical Management And Prompt Risk-Aligned Intervention In Barrett’s Esophagus\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-27 03:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/CSTL\">Castle Biosciences</a> Inc Says Tissuecypher® Provides Actionable Risk Insights That Influence Clinical Management And Prompt Risk-Aligned Intervention In Barrett’s Esophagus</title></head><body><p><span>Oct 26 (Reuters)</span><span> - </span>Castle Biosciences Inc <span>CSTL.O</span>:</p><ul><li><p>NEW DATA AT AMERICAN COLLEGE OF GASTROENTEROLOGY ANNUAL MEETING SHOW TISSUECYPHER® PROVIDES ACTIONABLE RISK INSIGHTS THAT INFLUENCE CLINICAL MANAGEMENT AND PROMPT RISK-ALIGNED INTERVENTION IN BARRETT’S ESOPHAGUS</p></li><li><p>CASTLE BIOSCIENCES INC - TISSUECYPHER SHOWS 34% AND 62% FIVE-YEAR PROGRESSION RISK</p></li></ul><p>Source text: <span>ID:nGNX4gd6fY</span></p><p>Further company coverage: <span>CSTL.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251026:nFWN3W6010:1","article_id":"2578654818","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578654818","pubTimestamp":1761505787,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Castle Biosciences Inc Says Tissuecypher Provides Actionable Risk Insights That Influence Clinical Management And Prompt Risk-Aligned Intervention In Barrett’s EsophagusOct 26 (Reuters) - Castle","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","CSTL":"Castle Biosciences, Inc."},"translate_title":"BRIEF-Castle Biosciences Inc表示Tissuecypher®提供可操作的风险见解，影响巴雷特食管的临床管理并提示风险一致的干预","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSTL":0.9},"content_text":"BRIEF-Castle Biosciences Inc Says Tissuecypher® Provides Actionable Risk Insights That Influence Clinical Management And Prompt Risk-Aligned Intervention In Barrett’s EsophagusOct 26 (Reuters) - Castle Biosciences Inc CSTL.O:NEW DATA AT AMERICAN COLLEGE OF GASTROENTEROLOGY ANNUAL MEETING SHOW TISSUECYPHER® PROVIDES ACTIONABLE RISK INSIGHTS THAT INFLUENCE CLINICAL MANAGEMENT AND PROMPT RISK-ALIGNED INTERVENTION IN BARRETT’S ESOPHAGUSCASTLE BIOSCIENCES INC - TISSUECYPHER SHOWS 34% AND 62% FIVE-YEAR PROGRESSION RISKSource text: ID:nGNX4gd6fYFurther company coverage: CSTL.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}